Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ticagrelor

FDA-approved product (tablet, oral), marketed as Brilinta, Ticagrelor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ticagrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Coronary artery disease
  • Myocardial infarction
  • Peripheral vascular disease
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ticagrelor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ticagrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction

    NCT05122741 · start 2021-12-01

    Registered record
    Registry ID
    NCT05122741
    Conditions
    Myocardial Infarction; Myocardial Fibrosis; Myocardial Remodeling, Ventricular
    Interventions
    P2Y12 Potent Inhibitor + Aspirin for STEMI patients; Clopidogrel + Aspirin for CCS patients
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2023-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Myocardial Fibrosis; Myocardial Remodeling, Ventricular
    InterventionP2Y12 Potent Inhibitor + Aspirin for STEMI patients; Clopidogrel + Aspirin for CCS patients
    PhaseNot recorded
    Registry statusUnknown

  • Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

    NCT04695106 · start 2021-10-25

    Registered record
    Registry ID
    NCT04695106
    Conditions
    Atrial Fibrillation; Antithrombotic Therapy; Acute Coronary Syndrome; Percutaneous Coronary Interventions
    Interventions
    Ticagrelor; Dabigatran Etexilate; Aspirin; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-10-25
    Completion
    2026-08-31
    Enrolment
    1,194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Antithrombotic Therapy; Acute Coronary Syndrome; Percutaneous Coronary Interventions
    InterventionTicagrelor; Dabigatran Etexilate; Aspirin; Clopidogrel
    PhasePhase 4
    Registry statusRecruiting

  • OPTImal Management of Antithrombotic Agents: OPTIMA-5

    NCT04116931 · start 2020-06-22

    Registered record
    Registry ID
    NCT04116931
    Conditions
    Acute Coronary Syndrome (ACS)
    Interventions
    Switch ticagrelor to clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06-22
    Completion
    2021-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome (ACS)
    InterventionSwitch ticagrelor to clopidogrel
    PhasePhase 4
    Registry statusUnknown

  • Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

    NCT04088123 · start 2020-04-01

    Registered record
    Registry ID
    NCT04088123
    Conditions
    Thrombosis; Artery
    Interventions
    Ticagrelor Oral Tablet [Brilinta]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2020-04-01
    Completion
    2020-09-23
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis; Artery
    InterventionTicagrelor Oral Tablet [Brilinta]
    PhaseNot recorded
    Registry statusWithdrawn

  • Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

    NCT03775746 · start 2019-01-08

    Registered record
    Registry ID
    NCT03775746
    Conditions
    Acute Coronary Syndrome
    Interventions
    Clopidogrel 75Mg Tablet; Rivaroxaban 2.5Mg Tablet; Ticagrelor 90Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-08
    Completion
    2021-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionClopidogrel 75Mg Tablet; Rivaroxaban 2.5Mg Tablet; Ticagrelor 90Mg Tablet
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

    NCT03620760 · start 2018-08-07

    Registered record
    Registry ID
    NCT03620760
    Conditions
    Unstable Angina Pectoris; Coronary Stent Implantation
    Interventions
    Ticagrelor 90 mg; Ticagrelor 45 mg; Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-07
    Completion
    2020-12-31
    Enrolment
    2,036

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnstable Angina Pectoris; Coronary Stent Implantation
    InterventionTicagrelor 90 mg; Ticagrelor 45 mg; Aspirin
    PhasePhase 4
    Registry statusUnknown

  • STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

    NCT03184805 · start 2017-06-23

    Registered record
    Registry ID
    NCT03184805
    Conditions
    Coronary Artery Disease
    Interventions
    Continuing aspirin; Stopping aspirin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2017-06-23
    Completion
    2018-04-09
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionContinuing aspirin; Stopping aspirin
    PhaseNot applicable
    Registry statusTerminated

  • GLOBAL LEADERS Adjudication Sub-Study

    NCT03231059 · start 2017-06-01

    Registered record
    Registry ID
    NCT03231059
    Conditions
    Coronary Artery Disease; Platelet-aggregation Inhibitors
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2020-05-30
    Enrolment
    7,365

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Platelet-aggregation Inhibitors
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • EROSION II: OCT Guided PPCI in STEMI

    NCT03062826 · start 2017-01-11

    Registered record
    Registry ID
    NCT03062826
    Conditions
    ST-segment Elevation Myocardial Infarction
    Interventions
    dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-01-11
    Completion
    2023-03-01
    Enrolment
    347

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST-segment Elevation Myocardial Infarction
    Interventiondual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
    PhaseNot recorded
    Registry statusUnknown

  • Study of AggreGuide A-100 (ADP) Assay

    NCT03111420 · start 2017-01-09

    Registered record
    Registry ID
    NCT03111420
    Conditions
    Risk Factor, Cardiovascular; Platelet Dysfunction Due to Drugs
    Interventions
    P2Y12 inhibitor; Platelet function test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-01-09
    Completion
    2018-06
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRisk Factor, Cardiovascular; Platelet Dysfunction Due to Drugs
    InterventionP2Y12 inhibitor; Platelet function test
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

    NCT02910778 · start 2016-10

    Registered record
    Registry ID
    NCT02910778
    Conditions
    Ischemia
    Interventions
    Atorvastatin; Placebo; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10
    Completion
    2017-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemia
    InterventionAtorvastatin; Placebo; Ticagrelor
    PhasePhase 4
    Registry statusCompleted

  • Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients

    NCT02929888 · start 2016-10

    Registered record
    Registry ID
    NCT02929888
    Conditions
    Acute Myocardial Infarction
    Interventions
    Lysine Acetilsalicilate; Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-10
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction
    InterventionLysine Acetilsalicilate; Aspirin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor

    NCT02698618 · start 2016-03

    Registered record
    Registry ID
    NCT02698618
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Diagnostic; Randomization; PCI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-03
    Completion
    2017-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDiagnostic; Randomization; PCI
    PhasePhase 4
    Registry statusUnknown

  • Registry of Acute Coronary Syndrome From University Hospital of Vigo

    NCT03664388 · start 2016-02-01

    Registered record
    Registry ID
    NCT03664388
    Conditions
    Acute Coronary Syndrome
    Interventions
    Dual antiplatelet therapy with ticagrelor/prasuglre
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-02-01
    Completion
    2020-02-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionDual antiplatelet therapy with ticagrelor/prasuglre
    PhaseNot recorded
    Registry statusUnknown

  • Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

    NCT02539160 · start 2016-02

    Registered record
    Registry ID
    NCT02539160
    Conditions
    Coronary Artery Disease; Diabetes Mellitus
    Interventions
    ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02
    Completion
    2020-06-17
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Diabetes Mellitus
    Interventionticagrelor
    PhasePhase 4
    Registry statusCompleted